Brookstone Capital Management lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 63,479 shares of the biopharmaceutical company’s stock after selling 6,727 shares during the quarter. Brookstone Capital Management’s holdings in Gilead Sciences were worth $4,901,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in GILD. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 11.6% during the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after buying an additional 3,221,439 shares during the period. Swedbank boosted its stake in Gilead Sciences by 103.7% during the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after buying an additional 1,988,987 shares during the period. Natixis boosted its stake in Gilead Sciences by 4,550.6% during the second quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock worth $135,555,000 after buying an additional 1,872,389 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Gilead Sciences by 1,631.7% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 997,656 shares of the biopharmaceutical company’s stock worth $70,674,000 after buying an additional 940,044 shares during the period. Finally, Sanders Capital LLC boosted its stake in Gilead Sciences by 7.0% during the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after buying an additional 696,200 shares during the period. 78.09% of the stock is owned by institutional investors.
Several research firms have recently commented on GILD. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday. Mizuho set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, October 26th. Barclays raised their price objective on shares of Gilead Sciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 26th. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, October 31st. Finally, Robert W. Baird lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price objective for the company. in a research note on Thursday, July 26th. Twelve research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $87.84.
Shares of NASDAQ:GILD opened at $71.18 on Friday. The company has a market capitalization of $93.76 billion, a P/E ratio of 11.29, a PEG ratio of -2.81 and a beta of 1.01. Gilead Sciences, Inc. has a fifty-two week low of $64.27 and a fifty-two week high of $89.54. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.39 and a current ratio of 3.45.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.63 by $0.21. The firm had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same quarter last year, the company earned $2.27 earnings per share. As a group, analysts predict that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be issued a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.20%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
TRADEMARK VIOLATION NOTICE: This article was first posted by WKRB News and is the property of of WKRB News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.wkrb13.com/2018/11/10/gilead-sciences-inc-gild-shares-sold-by-brookstone-capital-management.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: Why do company’s buyback their stock?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.